BRPI0519466A2 - dispersço sàlida estÁvel de um derivado de alcalàide de vinca e processo para a fabricaÇço do mesmo - Google Patents

dispersço sàlida estÁvel de um derivado de alcalàide de vinca e processo para a fabricaÇço do mesmo

Info

Publication number
BRPI0519466A2
BRPI0519466A2 BRPI0519466-0A BRPI0519466A BRPI0519466A2 BR PI0519466 A2 BRPI0519466 A2 BR PI0519466A2 BR PI0519466 A BRPI0519466 A BR PI0519466A BR PI0519466 A2 BRPI0519466 A2 BR PI0519466A2
Authority
BR
Brazil
Prior art keywords
solidly
manufacture
stable dispersion
vinca
derivative
Prior art date
Application number
BRPI0519466-0A
Other languages
English (en)
Inventor
Elie Leverd
Marie-Dominique Ibarra
Joeel Bougaret
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/025,348 external-priority patent/US20060147518A1/en
Priority claimed from FR0414069A external-priority patent/FR2880274B1/fr
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of BRPI0519466A2 publication Critical patent/BRPI0519466A2/pt
Publication of BRPI0519466B1 publication Critical patent/BRPI0519466B1/pt
Publication of BRPI0519466B8 publication Critical patent/BRPI0519466B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

DISPERSçO SàLIDA ESTÁVEL DE UM DERIVADO DE ALCALàIDE DE VINCA E PROCESSO PARA A FABRICAÇçO DO MESMO. A presente invenção refere-se às dispersões sólidas e estáveis de um derivado hidrossolúvel de alcalóidels de vinca em pelo menos um polietileno glicol com uma massa molecular entre 800 e 30.000.
BRPI0519466A 2004-12-30 2005-12-20 dispersão sólida estável de um derivado de alcalóide de vinca e processo para a fabricação do mesmo BRPI0519466B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR0414069 2004-12-30
US11/025,348 2004-12-30
US11/025,348 US20060147518A1 (en) 2004-12-30 2004-12-30 Stable solid dispersion of a derivative of vinca alkaloid and process for manufacturing it
FR0414069A FR2880274B1 (fr) 2004-12-30 2004-12-30 Dispersion solide stable d'un derive d'alcaloides de vinca et son procede de fabrication
PCT/EP2005/056965 WO2006069938A1 (en) 2004-12-30 2005-12-20 Stable solid dispersion of a derivative of vinca alkaloid and process for manufacturing it

Publications (3)

Publication Number Publication Date
BRPI0519466A2 true BRPI0519466A2 (pt) 2009-02-03
BRPI0519466B1 BRPI0519466B1 (pt) 2020-10-20
BRPI0519466B8 BRPI0519466B8 (pt) 2021-05-25

Family

ID=36046982

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0519466A BRPI0519466B8 (pt) 2004-12-30 2005-12-20 dispersão sólida estável de um derivado de alcalóide de vinca e processo para a fabricação do mesmo

Country Status (22)

Country Link
US (1) US9061015B2 (pt)
EP (1) EP1830817B1 (pt)
JP (1) JP5256739B2 (pt)
KR (1) KR101320408B1 (pt)
AR (1) AR052079A1 (pt)
AU (1) AU2005321346B2 (pt)
BR (1) BRPI0519466B8 (pt)
CA (1) CA2591056C (pt)
CY (1) CY1113868T1 (pt)
DK (1) DK1830817T3 (pt)
ES (1) ES2401992T3 (pt)
HR (1) HRP20130276T1 (pt)
IL (1) IL184095A (pt)
MX (1) MX2007008059A (pt)
NZ (1) NZ554793A (pt)
PL (1) PL1830817T3 (pt)
PT (1) PT1830817E (pt)
RS (1) RS52697B (pt)
RU (1) RU2412687C2 (pt)
SI (1) SI1830817T1 (pt)
TW (1) TWI419714B (pt)
WO (1) WO2006069938A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1989212B1 (en) * 2006-02-17 2013-06-19 Cascade Prodrug Inc. Treatment of hyperproliferative diseases with vinca alkaloid n-oxide and analogs
WO2008097658A1 (en) * 2007-02-09 2008-08-14 Poniard Pharmaceuticals, Inc. Encapsulated picoplatin
FR2918567B1 (fr) * 2007-07-11 2012-08-03 Pf Medicament Composition pharmaceutique stable d'un sel hydrosoluble de vinorelbine.
FR2918566B1 (fr) 2007-07-11 2009-10-09 Pierre Fabre Medicament Sa Composition pharmaceutique stable d'un sel hydrosoluble de vinflunine.
BR112018067637A2 (pt) 2016-03-09 2019-01-02 Synbias Pharma Ag monotartrato de vinorelbina e seu uso farmacêutico

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6811088B2 (en) * 1993-05-28 2004-11-02 Symbol Technologies, Inc. Portable data collection system
HN1998000115A (es) 1997-08-21 1999-06-02 Warner Lambert Co Formas de dosificación farmacéuticas sólidas
NL1009780C2 (nl) 1998-07-31 2000-02-01 Peter Hubertus Elisabeth Van D Plantpot.
DE10000792A1 (de) * 2000-01-11 2001-07-19 Bernhard C Lippold Formulierungen von Wirkstoffen in Form einer festen Dispersion
US20020004070A1 (en) * 2000-02-24 2002-01-10 Rudnic Edward M. Antineoplastic product, use and formulation thereof
WO2001095939A1 (en) 2000-06-12 2001-12-20 Smithkline Beecham Corporation Novel solid dispersion compositions
IT1320176B1 (it) * 2000-12-22 2003-11-26 Nicox Sa Dispersioni solide di principi attivi nitrati.
US20030212102A1 (en) * 2001-06-12 2003-11-13 Koretke Todd W Novel solid dispersion compositions
DE60331920D1 (de) * 2002-05-31 2010-05-12 Rp Scherer Technologies Llc Orale pharmazeutische zusammensetzung für weichkapseln mit vinorelbin und behandlungsverfahren
US20050048119A1 (en) * 2002-09-20 2005-03-03 Avinash Nangia Controlled release composition with semi-permeable membrane and poloxamer flux enhancer

Also Published As

Publication number Publication date
IL184095A0 (en) 2007-10-31
KR101320408B1 (ko) 2013-10-30
WO2006069938A1 (en) 2006-07-06
MX2007008059A (es) 2007-07-17
AR052079A1 (es) 2007-02-28
JP5256739B2 (ja) 2013-08-07
KR20070094598A (ko) 2007-09-20
US20080089935A1 (en) 2008-04-17
CA2591056C (en) 2013-11-12
HRP20130276T1 (hr) 2013-04-30
BRPI0519466B1 (pt) 2020-10-20
PT1830817E (pt) 2013-04-01
CY1113868T1 (el) 2016-07-27
PL1830817T3 (pl) 2013-06-28
DK1830817T3 (da) 2013-04-02
AU2005321346A1 (en) 2006-07-06
SI1830817T1 (sl) 2013-04-30
IL184095A (en) 2015-08-31
AU2005321346A8 (en) 2011-10-13
RU2007124572A (ru) 2009-01-10
EP1830817B1 (en) 2013-01-02
EP1830817A1 (en) 2007-09-12
US9061015B2 (en) 2015-06-23
JP2008526711A (ja) 2008-07-24
ES2401992T3 (es) 2013-04-26
BRPI0519466B8 (pt) 2021-05-25
TWI419714B (zh) 2013-12-21
CA2591056A1 (en) 2006-07-06
RU2412687C2 (ru) 2011-02-27
AU2005321346B2 (en) 2011-06-23
NZ554793A (en) 2010-04-30
TW200635619A (en) 2006-10-16
RS52697B (sr) 2013-08-30

Similar Documents

Publication Publication Date Title
BRPI0508758A (pt) processo para a preparação de cloridrato de oxicodona tendo menos que 25 ppm de 14 - hidroxicodeinona
WO2008033643A3 (en) Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin
MX2007012237A (es) Amilina y agonistas de amilina para tratar enfermedades y trastornos siquiatricos.
TW200708258A (en) Tobacco compositions
BRPI0717404A2 (pt) Processo para produzir polímero modifcado, polímero modificado obtido pelo processo e composição de borracha de borracha contendo o mesmo
NO20074431L (no) Pyrrolopyrimidiner nyttige som proteinkinaseinhibitorer
MXPA05013290A (es) Composiciones oftalmicas que contienen una combinacion sinergistica de dos polimeros.
DK2321321T3 (da) Triazolo [4,5-d]pyramidinderivater og anvendelse deraf som purinreceptorantagonister
DK1678244T3 (da) Varmeformfaste polymethacrylimidskumplast med små porer
CY1106902T1 (el) Κρυσταλλικη μορφη μηλεϊνικης ασεναπινης
MX2012004771A (es) Potenciadores alostericos mglur4, composiciones y metodos para tratar disfunciones neurologicas.
MX2009012645A (es) Formulaciones y metodos para tratar el ojo seco.
CR9750A (es) Dispersiones solidas amorfas de 7-cloro-n,n,5-trimetil-4-oxo-3-fenil-3,5-dihidro-4h-prirdazino[4,5-b]indol-1-acetamida
UY29149A1 (es) Tiazolil-dihidro-indazoles
SG145724A1 (en) Recombinant lubricin molecules and uses thereof
BRPI0511491A (pt) fibra polimérica carregada, utilização da mesma, produto à base de fibras, processo de fabricação de uma fibra polimérica carregada, e de um produto à base de fibras e de uma massa de pega hidráulica, e composição
ECSP066822A (es) Macrólidos y métodos para producir los mismos
DE502004001971D1 (de) Wässrige zusammensetzung und deren verwendung zur papierherstellung
WO2007067519A3 (en) The use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions
PL1888013T3 (pl) Biologicznie przyswajalne wypełniacze składające się z liposomów fosfolipidowych i kwasu hialuronowego i/lub jego pochodnych
WO2007030761A3 (en) Acyclic 1,4-diamines and uses thereof
BRPI0519466B8 (pt) dispersão sólida estável de um derivado de alcalóide de vinca e processo para a fabricação do mesmo
WO2009059239A3 (en) REDUCING Aβ42 LEVELS AND Aβ AGGREGATION
BRPI0520129A2 (pt) uso de 5'-metiltioadenosina (mta) na prevenÇço e/ou no tratamento de doenÇas auto-imunes e/ou rejeiÇço de transplante
ITMI20052515A1 (it) Formulazione farmaceutica per il trattamento della osteoartrite

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 20/10/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/12/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 20A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2860 DE 28-10-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.